Lung | Interview with Suresh S Ramalingam, MD

1:07:52
 
Share
 

Manage episode 229585821 series 1464173
By Discovered by Player FM and our community — copyright is owned by the publisher, not Player FM, and audio streamed directly from their servers.

Lung Cancer Update – Part 1: Our interview with Dr Ramalingam highlights the following topics as well as cases from his practice:

  • Mechanisms of resistance to osimertinib and management of non-small cell lung cancer (NSCLC) with EGFR tumor mutations in patients who experience disease progression on first-line osimertinib: 0m0s
  • Results of the Phase III IMpower150 trial: Atezolizumab and chemotherapy with or without bevacizumab versus bevacizumab and chemotherapy for chemotherapy-naïve metastatic nonsquamous NSCLC: 3m55s
  • Role of bevacizumab in combination with EGFR tyrosine kinase inhibitors (TKIs) for patients with NSCLC and EGFR tumor mutations: 5m22s
  • Emerging data with novel TKIs for patients with NSCLC and MET gene amplifications: 8m0s
  • Incidence and clinical significance of MET amplifications and MET exon 14 mutations: 10m22s
  • Use of liquid biopsies to detect mutations in patients with lung cancer: 13m52s
  • FLAURA study results: Osimertinib versus erlotinib or gefitinib as first-line therapy for advanced NSCLC with an EGFR tumor mutation: 17m11s
  • Ongoing evaluation of EGFR TKIs for Stage III NSCLC: 19m4s
  • Perspective on the use of osimertinib in the adjuvant setting: 21m52s
  • Case: A 62-year-old man and never smoker with Stage IV NSCLC and an EGFR exon 19 deletion receives osimertinib as first-line treatment: 23m30s
  • Response to osimertinib in patients with brain metastases: 27m5s
  • Case: A 44-year-old man and never smoker with metastatic NSCLC and an ALK rearrangement receives alectinib after disease progression on crizotinib with an anti-PD-1 antibody: 31m3s
  • ALTA-1L: A Phase III trial evaluating brigatinib versus crizotinib for advanced NSCLC with an ALK rearrangement: 35m44s
  • Efficacy and tolerability of lorlatinib in patients with NSCLC and an ALK rearrangement: 39m43s
  • Case: A 52-year-old woman and nonsmoker with metastatic NSCLC and a BRAF V600E tumor mutation receives dabrafenib and trametinib as second-line therapy: 42m13s
  • Use of targeted therapy as first-line treatment for patients with NSCLC: 44m42s
  • Case: A 58-year-old man with locally advanced squamous cell carcinoma of the lung receives durvalumab as consolidation therapy after chemoradiation therapy: 46m59s
  • Overall survival with the addition of durvalumab to chemoradiation therapy for patients with Stage III NSCLC: 48m45s
  • Pulmonary toxicity associated with durvalumab: 50m47s
  • Ongoing investigation of immune checkpoint inhibitors in the adjuvant setting: 55m30s
  • Management of metastatic small cell lung cancer: 58m5s
  • Novel agents under investigation for small cell lung cancer: 1h0m15s
  • Emerging research aimed at enhancing the efficacy of immune checkpoint inhibitors: 1h5m2s

Select publications

2120 episodes available. A new episode about every 3 days averaging 77 mins duration .